Amgen Aranesp European Approval For Dialysis Use Permits Bi-Weekly Dosing
Chronic renal failure patients receiving Amgen's Aranesp "have been treated successfully with doses administered once every two weeks," European product labeling states.
Chronic renal failure patients receiving Amgen's Aranesp "have been treated successfully with doses administered once every two weeks," European product labeling states.